Alyra Biotech

Alyra Biotech is an Australian clinical-stage biotechnology company focused on transforming the treatment landscape for women's health, particularly chronic pelvic pain and endometriosis. The company's core strategy involves the development of localized, sustained-release therapies using a proprietary intravaginal ring delivery platform. Their lead candidate, ALY-101, is a non-opioid therapeutic designed to provide targeted relief for debilitating pelvic pain conditions such as vulvodynia. By focusing on local delivery, Alyra aims to maximize therapeutic efficacy at the site of pain while significantly reducing the systemic side effects associated with oral medications. The company is backed by prominent life science investors and collaborates with leading clinical experts in gynecology and pain management.